Riskpilot← Back to searchSign inGet full accessYNOLENS AS
ASActiveOrg 996619036Mørkvedveien 29, 1814 AskimManufacture of pharmaceutical preparations · NACE 2120Est. 20110 employeeswww.ynolens.no
Revenue 2024
NOK 1,4M
+54% vs 2023
EBITDA margin
-1.0%
+98% vs 2023
Equity ratio
-281.9%
Financial strength
Net profit 2024
NOK -76K
+88% vs 2023
| Revenue | NOK 1,4M | +54% |
| EBITDA | NOK -13K | +98% |
| Net profit | NOK -76K | +88% |
| Total assets | NOK 326K | -4% |
| Equity | NOK -919K | +6% |
| Employees | 0 | — |
Legal name
YNOLENS AS
Org number
996619036
Legal form
Aksjeselskap
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
21. mars 2011
Share capital
NOK 450 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder og daglig leder hver for seg.
Company purpose
Produksjon og salg av medisinske hjelpemidler og tjenester i forbindelse med skadesanering og andre produkter som naturlig faller sammen med dette. Kjøp og salg av aksjer og andre verdipapirer, investering i andre selskaper. Kjøp og salg av fast eiendom. Virksomhet som ligger naturlig i tilknytning til punktene ovenfor.
Address
Mørkvedveien 29, 1814 Askim
Website
www.ynolens.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 845 | 1 165 | 693 | 895 | 1 382 |
| Staff expenses | −0 | −1 | −0 | −0 | −0 |
| EBITDA | 40 | 83 | −148 | −581 | −13 |
| Depreciation & amort. | −46 | −32 | −35 | −35 | −61 |
| EBIT | −6 | 51 | −183 | −616 | −75 |
| Net financials | −25 | 16 | −0 | −14 | −2 |
| Profit before tax | −31 | 67 | −183 | −630 | −76 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −31 | 67 | −183 | −630 | −76 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 489 | 384 | 365 | 340 | 326 |
| Equity | −233 | −166 | −349 | −980 | −919 |
| Long-term debt | 92 | 36 | 550 | 1 259 | 1 145 |
| Short-term debt | 630 | 515 | 164 | 60 | 101 |
| Total debt | 722 | 550 | 714 | 1 319 | 1 246 |
EBITDA margin
-1.0%
This company
15.8%
Market median
-106% vs market
20202024
Equity ratio
-281.9%
This company
38.2%
Market median
-838% vs market
20202024
Return on equity
-7613400.0%
This company
18.4%
Market median
-41377274% vs market
20202024
Net profit margin
-5.5%
This company
8.1%
Market median
-168% vs market
20202024
Asset turnover
4.24×
This company
1.12×
Market median
+279% vs market
20202024
Debt / equity
1.35×
This company
0.62×
Market median
-118% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Gulddesign As
YNOLENS AS